Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Gyre Therapeutics Inc (Gyre), a subsidiary of GNI Group Ltd, is a biopharmaceutical company that develops and commercializes therapeutic drugs. The company's pipeline products include hydronidone (F351) targets metabolic dysfunction associated steatohepatitis (MASH-associated liver fibrosis); pirfenidone for idiopathic pulmonary fibrosis; F573 treats acute-on-chronic liver failure; F528 and F230 and chronic obstructive pulmonary disease and pulmonary arterial hypertension, among others. It operates in the US and China. Gyre Therapeutics is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
Suite 150, 12770 High Bluff Drive, San Diego, California, 92130
Website
www.gyretx.com
Telephone
1 858 5677770
No of Employees
618
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GYRE (NASD)
Revenue (2024)
$116.6M
10.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-58.4%
(2024 vs 2023)
Market Cap*
$537.3M
Net Profit Margin (2024)
XYZ
-62.3%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| Hydronidone (F351): Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver Fibrosis) |
| Pirfenidone: Idiopathic Pulmonary Fibrosis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In July, the company secured approval from China’s National Medical Products Administration for avatrombopag maleate tablets to treat thrombocytopenia associated with chronic liver disease in adult patients. |
| 2023 | Acquisitions/Mergers/Takeovers | In October, the company merged with GNI Group. |
| 2023 | Acquisitions/Mergers/Takeovers | In October, the company merged with Beijing Continent Pharmaceuticals. |
Competitor Comparison
| Key Parameters | Gyre Therapeutics Inc | Kura Oncology Inc | Cartesian Therapeutics Inc | Actinium Pharmaceuticals Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | San Diego | Frederick | New York City |
| State/Province | California | California | Maryland | New York |
| No. of Employees | 618 | 260 | 75 | 25 |
| Entity Type | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ping Zhang | Chairman | Executive Board | 2025 | 51 |
| Han Ying, Ph.D. | Chief Executive Officer; Director | Executive Board | 2023 | 60 |
| Songjiang Ma | Director; President | Executive Board | 2023 | 69 |
| Ruoyu Chen | Chief Financial Officer | Senior Management | 2023 | 55 |
| Weiguo Ye | Chief Operating Officer | Senior Management | 2023 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer